Evotec SE (EVT) - Net Assets
Based on the latest financial reports, Evotec SE (EVT) has net assets worth €699.62 Million EUR (≈ $817.93 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.64 Billion ≈ $1.92 Billion USD) and total liabilities (€940.19 Million ≈ $1.10 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EVT current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €699.62 Million |
| % of Total Assets | 42.66% |
| Annual Growth Rate | 15.22% |
| 5-Year Change | -40.94% |
| 10-Year Change | 280.35% |
| Growth Volatility | 39.13 |
Evotec SE - Net Assets Trend (2003–2025)
This chart illustrates how Evotec SE's net assets have evolved over time, based on quarterly financial data. Check Evotec SE (EVT) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Evotec SE (2003–2025)
The table below shows the annual net assets of Evotec SE from 2003 to 2025. For live valuation and market cap data, see EVT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €813.70 Million ≈ $951.31 Million |
-14.57% |
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
-14.95% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
-5.67% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
-13.83% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
+90.02% |
| 2020-12-31 | €725.01 Million ≈ $847.62 Million |
+51.99% |
| 2019-12-31 | €477.03 Million ≈ $557.70 Million |
+12.27% |
| 2018-12-31 | €424.88 Million ≈ $496.73 Million |
+28.07% |
| 2017-12-31 | €331.75 Million ≈ $387.85 Million |
+55.07% |
| 2016-12-31 | €213.94 Million ≈ $250.11 Million |
+14.35% |
| 2015-12-31 | €187.09 Million ≈ $218.73 Million |
+18.13% |
| 2014-12-31 | €158.38 Million ≈ $185.17 Million |
-0.37% |
| 2013-12-31 | €158.97 Million ≈ $185.85 Million |
+4.21% |
| 2012-12-31 | €152.55 Million ≈ $178.34 Million |
+3.60% |
| 2011-12-31 | €147.25 Million ≈ $172.14 Million |
+11.01% |
| 2010-12-31 | €132.64 Million ≈ $155.07 Million |
+18.97% |
| 2009-12-31 | €111.49 Million ≈ $130.34 Million |
-25.61% |
| 2008-12-31 | €149.86 Million ≈ $175.20 Million |
-12.13% |
| 2007-12-31 | €170.55 Million ≈ $199.39 Million |
+24.33% |
| 2006-12-31 | €137.18 Million ≈ $160.37 Million |
-7.73% |
| 2005-12-31 | €148.67 Million ≈ $173.81 Million |
+140.85% |
| 2004-12-31 | €61.73 Million ≈ $72.17 Million |
+71.32% |
| 2003-12-31 | €36.03 Million ≈ $42.12 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Evotec SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77588700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €177.78 Million | 21.85% |
| Other Comprehensive Income | €-45.11 Million | -5.54% |
| Other Components | €1.46 Billion | 179.05% |
| Total Equity | €813.70 Million | 100.00% |
Evotec SE Competitors by Market Cap
The table below lists competitors of Evotec SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
We Buy Cars Hlds Ltd
JSE:WBC
|
$724.21 Million |
|
Shanghai Maling Aquarius Co Ltd
SHG:600073
|
$724.52 Million |
|
Paul Hartmann AG
F:PHH2
|
$724.56 Million |
|
Odfjell SE
OL:ODF
|
$724.76 Million |
|
Argo Properties NV
TA:ARGO
|
$724.13 Million |
|
Anhui Estone Materials Technology Co Ltd
SHG:688733
|
$723.82 Million |
|
Prashkovsky
TA:PRSK
|
$723.80 Million |
|
Safe Bulkers Inc
NYSE:SB
|
$723.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evotec SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 952,525,000 to 813,704,000, a change of -138,821,000 (-14.6%).
- Net loss of 103,517,000 reduced equity.
- Share repurchases of 1,548,000 reduced equity.
- Other comprehensive income decreased equity by 37,758,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-103.52 Million | -12.72% |
| Share Repurchases | €1.55 Million | -0.19% |
| Other Comprehensive Income | €-37.76 Million | -4.64% |
| Other Changes | €4.00 Million | +0.49% |
| Total Change | €- | -14.57% |
Book Value vs Market Value Analysis
This analysis compares Evotec SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.76x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.76x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | €115.64 | €3.49 | x |
| 2002-12-31 | €31.28 | €3.49 | x |
| 2003-12-31 | €-69.44 | €3.49 | x |
| 2004-12-31 | €2.81 | €3.49 | x |
| 2005-12-31 | €5.53 | €3.49 | x |
| 2006-12-31 | €4.66 | €3.49 | x |
| 2007-12-31 | €2.37 | €3.49 | x |
| 2008-12-31 | €1.57 | €3.49 | x |
| 2009-12-31 | €1.04 | €3.49 | x |
| 2010-12-31 | €1.21 | €3.49 | x |
| 2011-12-31 | €1.27 | €3.49 | x |
| 2012-12-31 | €1.30 | €3.49 | x |
| 2013-12-31 | €1.31 | €3.49 | x |
| 2014-12-31 | €1.21 | €3.49 | x |
| 2015-12-31 | €1.35 | €3.49 | x |
| 2016-12-31 | €1.61 | €3.49 | x |
| 2017-12-31 | €2.28 | €3.49 | x |
| 2018-12-31 | €2.87 | €3.49 | x |
| 2019-12-31 | €3.19 | €3.49 | x |
| 2020-12-31 | €4.71 | €3.49 | x |
| 2021-12-31 | €8.28 | €3.49 | x |
| 2022-12-31 | €6.72 | €3.49 | x |
| 2023-12-31 | €6.33 | €3.49 | x |
| 2024-12-31 | €5.37 | €3.49 | x |
| 2025-12-31 | €4.58 | €3.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evotec SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.13%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.19x
- Recent ROE (-12.72%) is above the historical average (-14.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -35.26% | 0.00% | 0.00x | 1.00x | €-16.39 Million |
| 2002 | -127.77% | 0.00% | 0.00x | 1.00x | €-25.77 Million |
| 2003 | 0.00% | -930.49% | 0.09x | 0.00x | €-27.01 Million |
| 2004 | -48.25% | -1521.56% | 0.03x | 1.16x | €-35.57 Million |
| 2005 | -22.59% | -52.38% | 0.34x | 1.25x | €-48.45 Million |
| 2006 | -23.67% | -48.21% | 0.33x | 1.50x | €-46.19 Million |
| 2007 | -6.54% | -33.92% | 0.16x | 1.22x | €-28.21 Million |
| 2008 | -52.24% | -197.63% | 0.22x | 1.22x | €-93.27 Million |
| 2009 | -41.03% | -106.59% | 0.29x | 1.32x | €-56.58 Million |
| 2010 | 2.47% | 5.90% | 0.29x | 1.45x | €-9.96 Million |
| 2011 | 4.58% | 8.42% | 0.37x | 1.48x | €-7.98 Million |
| 2012 | 1.62% | 2.84% | 0.39x | 1.48x | €-12.78 Million |
| 2013 | -16.00% | -29.59% | 0.38x | 1.43x | €-41.33 Million |
| 2014 | -4.41% | -7.80% | 0.40x | 1.42x | €-22.82 Million |
| 2015 | 8.90% | 12.94% | 0.44x | 1.56x | €-2.03 Million |
| 2016 | 12.92% | 16.73% | 0.47x | 1.65x | €6.23 Million |
| 2017 | 7.33% | 9.42% | 0.39x | 2.02x | €-8.82 Million |
| 2018 | 19.85% | 22.42% | 0.49x | 1.82x | €41.77 Million |
| 2019 | 8.00% | 8.55% | 0.38x | 2.48x | €-9.55 Million |
| 2020 | 0.87% | 1.25% | 0.34x | 2.02x | €-66.17 Million |
| 2021 | 15.64% | 34.87% | 0.28x | 1.62x | €77.74 Million |
| 2022 | -14.80% | -23.38% | 0.33x | 1.90x | €-294.37 Million |
| 2023 | -7.49% | -10.74% | 0.35x | 2.01x | €-195.90 Million |
| 2024 | -20.59% | -24.60% | 0.42x | 2.01x | €-291.33 Million |
| 2025 | -12.72% | -13.13% | 0.44x | 2.19x | €-184.89 Million |
Industry Comparison
This section compares Evotec SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,638,364,748
- Average return on equity (ROE) among peers: -50.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evotec SE (EVT) | €699.62 Million | -35.26% | 1.34x | $724.20 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $61.84 Billion | 5.45% | 0.94x | $1.16 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $4.11 Billion | 11.00% | 0.48x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $252.47 Million | -46.64% | 0.59x | $154.57 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $17.35 Million | -23.30% | 0.22x | $9.05 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $63.59 Million |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more